science
Merck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
May 22, 9:46 AM·1m read1 source
thehindu.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Merck reported that its antibody-drug conjugate developed with a Chinese partner, when paired with Keytruda, sharply outperformed Keytruda alone in a subset of lung cancer patients.
Data showed the paired treatment delayed disease progression more effectively than Keytruda monotherapy.
A closely watched experimental Parkinson’s drug failed to meet its primary endpoint in a key clinical trial. The outcome was reported on May 21. Separately, a longevity startup backed by Sam Altman raised additional funds, reaching a valuation of $1.8 billion.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
